Previous 10 | Next 10 |
2023-04-03 03:51:40 ET Summary Sales of Takhzyro amounted to 44.1 billion Japanese yen in the 3rd quarter of 2022, an increase of 42.7% from the previous year. Takeda Pharmaceutical's revenue was $8,354 million in Q3 2022, showing phenomenal growth both year-on-year and quarter-on...
— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 3...
2023-03-30 11:28:34 ET A phase 4 study of Takeda Pharmaceutical Co.'s ( NYSE: TAK ) Entyvio met its primary endpoint in patients with ulcerative colitis. Results showed that at week 14, 31% of patients on Entyvio achieved remission from chronic or recurrent pouchitis ...
− The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus 10% Receiving Placebo. 1 − Superiority over Placebo Was Also D...
Takeda ( TSE:4502/NYSE:TAK ) announced that its Board of Directors today decided that it will propose a new candidate for independent external director at the 147 th Ordinary Meeting of Shareholders on June 28 th , 2023. The new candidate, Miki Tsusaka, will join the board effecti...
Expansion Contributes to the Company's Efforts Toward a Sustainable Global Plasma Supply to Support the Needs of People who Depend on Life-Saving Plasma Therapies . BioLife Plasma Services, part of the global biopharmaceutical company Takeda, today announced the opening of its 200 ...
2023-03-26 23:52:00 ET Summary Highlightll Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-o...
2023-03-24 04:44:46 ET Takeda Pharmaceutical ( NYSE: TAK ) said on Thursday that it will invest about ¥100B to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. The Japanese drugmaker noted that it was the company's largest eve...
2023-03-21 09:28:28 ET Ventyx Biosciences ( NASDAQ: VTYX ) traded higher pre-market Tuesday after Wells Fargo initiated its coverage with an Overweight recommendation citing an attractive entry point ahead of multiple catalysts over the next 12 – 18 months. The comp...
2023-03-20 06:45:56 ET TAK-279, an experimental tyrosine kinase 2 (TYK2) inhibitor developed by Takeda Pharmaceutical ( NYSE: TAK ), reached the primary and secondary endpoints in a mid-stage trial for patients with plaque psoriasis, the company announced. The Phase 2b study...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Pharmaceutical Company Limited American Depositary Shares Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
2024-07-04 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members servi...